MA32899B1 - Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine - Google Patents

Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine

Info

Publication number
MA32899B1
MA32899B1 MA33941A MA33941A MA32899B1 MA 32899 B1 MA32899 B1 MA 32899B1 MA 33941 A MA33941 A MA 33941A MA 33941 A MA33941 A MA 33941A MA 32899 B1 MA32899 B1 MA 32899B1
Authority
MA
Morocco
Prior art keywords
cytarabine
recognize
formulations containing
containing antibodies
cancer formulations
Prior art date
Application number
MA33941A
Other languages
Arabic (ar)
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32899(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32899B1 publication Critical patent/MA32899B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un anticorps reconnaissant spécifiquement CD38 et de la cytarabine.
MA33941A 2008-11-28 2011-06-13 Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine MA32899B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (fr) 2008-11-28 2008-11-28 Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
PCT/IB2009/055391 WO2010061359A1 (fr) 2008-11-28 2009-11-27 Associations antitumorales contenant des anticorps reconnaissant spécifiquement cd38 et de la cytarabine

Publications (1)

Publication Number Publication Date
MA32899B1 true MA32899B1 (fr) 2011-12-01

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33941A MA32899B1 (fr) 2008-11-28 2011-06-13 Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine

Country Status (40)

Country Link
US (1) US20120093806A1 (fr)
EP (2) EP2191842A1 (fr)
JP (2) JP2012510463A (fr)
KR (1) KR101715958B1 (fr)
CN (2) CN102264386A (fr)
AR (1) AR073425A1 (fr)
AU (1) AU2009321251B2 (fr)
BR (1) BRPI0921858B1 (fr)
CA (1) CA2745005C (fr)
CL (1) CL2011001232A1 (fr)
CO (1) CO6440556A2 (fr)
CR (1) CR20110282A (fr)
DK (1) DK2370096T5 (fr)
EA (1) EA027070B1 (fr)
EC (1) ECSP11011071A (fr)
ES (1) ES2638926T3 (fr)
HN (1) HN2011001423A (fr)
HR (1) HRP20171301T1 (fr)
HU (1) HUE035910T2 (fr)
IL (2) IL213118A (fr)
LT (1) LT2370096T (fr)
MA (1) MA32899B1 (fr)
MX (1) MX344973B (fr)
NI (1) NI201100107A (fr)
NZ (1) NZ593085A (fr)
PA (1) PA8849901A1 (fr)
PE (1) PE20120205A1 (fr)
PL (1) PL2370096T3 (fr)
PT (1) PT2370096T (fr)
PY (1) PY09043372A (fr)
RS (1) RS56248B1 (fr)
SG (1) SG171821A1 (fr)
SI (1) SI2370096T1 (fr)
SM (1) SMT201700403T1 (fr)
TN (1) TN2011000242A1 (fr)
TW (1) TWI436770B (fr)
UA (1) UA104160C2 (fr)
UY (1) UY32266A (fr)
WO (1) WO2010061359A1 (fr)
ZA (1) ZA201104064B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP6426093B2 (ja) 2012-09-25 2018-11-28 モルフォシス・アーゲー 組み合わせ及びその使用
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2017048872A1 (fr) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification de nouveaux agents diagnostiques et thérapeutiques par modulation de rhoh
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
EP3938394A1 (fr) 2019-03-15 2022-01-19 MorphoSys AG Anticorps anti-cd38 et compositions pharmaceutiques associées pour le traitement d'une maladie auto-immune à médiation par auto-anticorps
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
MX2022006882A (es) 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
WO2022152823A1 (fr) 2021-01-14 2022-07-21 Morphosys Ag Anticorps anti-cd38 et leurs utilisations
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (fr) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP2567976B1 (fr) * 2005-03-23 2017-07-19 Genmab A/S Anticorps diriges contre CD38 pour le traitement du myelome multiple
EP3569245A1 (fr) * 2006-09-26 2019-11-20 Genmab A/S Traitement combiné de tumeurs exprimant la cd38
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
WO2009094391A1 (fr) * 2008-01-23 2009-07-30 Xencor, Inc. Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
EP2191842A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine

Also Published As

Publication number Publication date
JP2012510463A (ja) 2012-05-10
EA027070B1 (ru) 2017-06-30
PL2370096T3 (pl) 2017-10-31
UY32266A (es) 2010-06-30
KR101715958B1 (ko) 2017-03-14
HUE035910T2 (en) 2018-05-28
IL213118A (en) 2017-08-31
DK2370096T3 (en) 2017-07-17
IL213115A0 (en) 2011-07-31
PT2370096T (pt) 2017-09-08
CN102264386A (zh) 2011-11-30
ES2638926T3 (es) 2017-10-24
PE20120205A1 (es) 2012-03-03
NI201100107A (es) 2011-09-26
BRPI0921858B1 (pt) 2022-11-16
AU2009321251A1 (en) 2010-06-03
IL213118A0 (en) 2011-07-31
CA2745005C (fr) 2020-08-11
SMT201700403T1 (it) 2017-11-15
MX344973B (es) 2017-01-12
EP2370096B1 (fr) 2017-05-31
PA8849901A1 (es) 2010-07-27
WO2010061359A1 (fr) 2010-06-03
JP2015205893A (ja) 2015-11-19
BRPI0921858A2 (en) 2018-10-09
AR073425A1 (es) 2010-11-03
CO6440556A2 (es) 2012-05-15
NZ593085A (en) 2012-12-21
CR20110282A (es) 2011-09-20
TW201023863A (en) 2010-07-01
JP6072854B2 (ja) 2017-02-01
US20120093806A1 (en) 2012-04-19
AU2009321251B2 (en) 2016-06-09
EP2191842A1 (fr) 2010-06-02
EP2370096A1 (fr) 2011-10-05
LT2370096T (lt) 2017-09-25
KR20110096551A (ko) 2011-08-30
SI2370096T1 (sl) 2017-10-30
DK2370096T5 (en) 2017-09-18
ECSP11011071A (es) 2011-07-29
EA201100868A1 (ru) 2011-10-31
CL2011001232A1 (es) 2012-02-10
MX2011005666A (es) 2011-09-30
CN107096022A (zh) 2017-08-29
HN2011001423A (es) 2014-01-13
IL213115A (en) 2017-08-31
UA104160C2 (uk) 2014-01-10
TWI436770B (zh) 2014-05-11
ZA201104064B (en) 2012-09-26
RS56248B1 (sr) 2017-11-30
HRP20171301T1 (hr) 2017-10-20
CA2745005A1 (fr) 2010-06-03
TN2011000242A1 (en) 2012-12-17
SG171821A1 (en) 2011-07-28
PY09043372A (es) 2013-11-01

Similar Documents

Publication Publication Date Title
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA32895B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA31984B1 (fr) Formulation d'anticorps
MA34816B1 (fr) Combinaisons antitumorales contenant des anticorps reconnaissant specifiquement le cd38 et du bortezomib
MA32894B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
MA33213B1 (fr) Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MY164577A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
MY161909A (en) Anti-her3 antibodies and uses thereof
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
CR10555A (es) Vacunas para malaria
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA34709B1 (fr) Compositions pharmaceutiques
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.